Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide by Hassan, Ferdaus et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Intracellular expression of toll-like receptor 4 in neuroblastoma 
cells and their unresponsiveness to lipopolysaccharide
Ferdaus Hassan, Shamima Islam, Gantsetseg Tumurkhuu, Yoshikazu Naiki, 
Naoki Koide, Isamu Mori, Tomoaki Yoshida and Takashi Yokochi*
Address: Department of Microbiology and Immunology, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan
Email: Ferdaus Hassan - hassan@aichi-med-u.ac.jp; Shamima Islam - shamima@aichi-med-u.ac.jp; Gantsetseg Tumurkhuu - gtsetseg@aichi-
med-u.ac.jp; Yoshikazu Naiki - naikiy@aichi-med-u.ac.jp; Naoki Koide - nao777nk@aichi-med-u.ac.jp; Isamu Mori - isamor@aichi-med-u.ac.jp; 
Tomoaki Yoshida - tomo@aichi-med-u.ac.jp; Takashi Yokochi* - yokochi@aichi-med-u.ac.jp
* Corresponding author    
Abstract
Background:  Recently it has been reported that, toll-like receptors (TLRs) are
expressed on a series of tumor cells, such as colon cancer, breast cancer, prostate
cancer, melanoma and lung cancer. Although some cancer cells like melanoma cells are
known to respond to lipopolysaccharide (LPS) via TLR4, not all cancer cells are positive
for TLR4. There is little information on the expression and function of TLR4 in
neuroblastoma cells. In this study, we investigated the expression of TLR4 in human
neuroblastoma NB-1 cell line.
Methods: Expression and localization of TLR4 were detected by reverse transcription-
polymerase chain reaction (RT-PCR) and flow cytometric analysis, respectively.
Activation of nuclear factor (NF)-κB by LPS was detected by degradation of IκB-α and
NF-κB luciferase assay. Activation and expression of mitogen-activated protein (MAP)
kinase and interferon regulatory factor (IRF)-3 was detected by immunoblot analysis.
Results: Human NB-1 neuroblastoma cells expressed intracellular form of TLR4, but
not the cell surface form. Further, NB-1 cells express CD14, MD2 and MyD88, which
are required for LPS response. However, LPS did not significantly induce NF-κB
activation in NB-1 cells although it slightly degraded IκB-α. NB-1 cells expressed no IRF-
3, which plays a pivotal role on the MyD88-independent pathway of LPS signaling.
Collectively, NB-1 cells are capable to avoid their response to LPS.
Conclusion: Although human NB-1 neuroblastoma cells possessed all the molecules
required for LPS response, they did not respond to LPS. It might be responsible for
intracellular expression of TLR4 or lack of IRF-3.
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Background
Recently it has been reported that, toll-like receptors
(TLRs) are expressed on a series of tumor cells, such as
colon cancer, breast cancer, prostate cancer, melanoma
and lung cancer [1]. In particular, melanoma cells are
reported to express TLR-4, respond to lipopolysaccharide
(LPS) and produce interleukin (IL)-8 [2]. Thus, a direct
link between tumor cell activation and LPS might be sug-
gested because some tumor cells constitutively express
TLR-4 [1]. However, not all tumor cells are positive for
TLR-4 and it seems to depend on the tissue from which
tumor cells originated.
Among neural cells, microglia cells are resident immune
cells of the brain and express almost all TLRs [3-6]. Apart
from microglia, astrocytes also differentially express TLRs
with a robust expression of TLR-2 and a low level of
expression of TLR-1, 4, 5 and 9 [5]. It is unclear whether
neuroblasts express TLR-4 or not. Considering that neu-
roblastoma cells do not express TLR-4 [2], neuroblasts are
unlikely to express TLR-4. In the present study, we exam-
ined two neuroblastoma cell lines to confirm the lack of
TLR-4 expression in neuroblatoma cells. Surprisingly, we
found that NB-1 neuroblastoma cells expressed intracellu-
lar TLR-4 but did not respond to LPS. Here, we discuss a
possible mechanism of the unresponsiveness of intracel-
lular TLR-4-expressing NB-1 neuroblastoma cells to LPS.
Methods
Materials
LPS from Esherichia coli O55:B5 was obtained from Sigma
Chemicals, St. Louis, MO, USA. Phycoerythrin (PE)-con-
jugated anti-human TLR-4 antibody was obtained from
eBioscience, San Diego, CA, USA. Antibody to human
TLR-4 was purchased from Santa-Cruz biotechnology,
Santa-Cruz, CA, USA. Antibody to phosphorylated inter-
feron regulatory factor (IRF)-3 was from Upstate, Lake
placid, New York, USA. Antibody to p38, c-Jun N-terminal
kinase (JNK1/2), IκB, IRF-3, and phosphorylated form of
p38 and JNK1/2 were purchased from Cell Signaling
Technology, Beverly, MA, USA. Human interferon (IFN)-γ
was purchased from Calbiochem, San Diego, CA, USA.
Human IL-1β was purchased from R & D Inc, Concord,
MA, USA.
Cell culture
Human neuroblastoma cell lines, NB-1 and SK-N-SH, and
human monocytic cell line, U-937, were obtained from
Riken Cell bank (Tsukuba, Japan). NB-1 and U-937 cells
were maintained in RPMI containing 5% heat inactivated
fetal calf serum (GIBCO-BRL, Gaithersburg, MD, USA)
and SK-N-SH cells was maintained in MEM with 10%
heat-inactivated fetal calf serum. Cells were cultured in the
presence of antibiotics at 37°C under 5% CO2.
Laser flow cytometric analysis
NB-1 cells were seeded (1 × 106/ml) in 35 mm dish for
overnight, trypsinized and washed with phosphate-buffed
saline (PBS). To detect cell surface expression of TLR4, the
cells were incubated with PE-conjugated anti-TLR4 anti-
body for 20 min in dark on ice, washed and resuspended
in PBS. To detect intracellular expression of TLR4, the cells
were fixed with a fixation buffer (eBioscience) in dark and
treated with a permeabilization buffer (eBioscience)
according to the instruction of the manufacturer. The cells
were stained with PE-conjugated anti-TLR-4 antibody.
Cell surface or intracellular TLR-4-positive cells were ana-
lyzed by a fluorescence activated cells sorter (BD FACS
Calibur, San Jose, CA, USA). PE-conjugated anti-rat iso-
type IgG was used as a negative control for the experi-
ments.
Reverse transcription-polymerase chain reaction (RT-
PCR)
RT-PCR was performed as described previously [7].
Briefly, NB-1 and SK-N-SH cells were seeded (1 × 106/ml)
in 35 mm dish for overnight, trypsinized and washed with
PBS. RNA was extracted from the cells with RNeasy mini
kit (Qiagen, Valencia, CA, USA). Semi-quantative RT-PCR
was carried out by using access quick RT-PCR system
(Promega, Madison, WI, USA). Primer Sequence for TLR4,
Forward 5 TGGATACGTTTCCTTATAAG 3 and Reverse 5
GAAATGGAGGCACCCCTTC 3 [8], CD14, forward 5
CTGCAACTTCTCCGAACCTC 3 and reverse 5 TAGGTC-
CTCGAGCGTCAGTT 5, MD2, forward 5 TTCCACCCT-
GTTTTCTTCCA 3 and reverse 5
AATCGTCATCAGATCCTCGC 3, MyD88, forward 5 GCA-
CATGGGCACATACAGAC 3 and reverse 5 TGGGTCCTT-
TCCAGAGTTTG 3 [9]. GAPDH for TLR4 and G3PDH for
CD14, MD2, MyD88 was used as an equal loading con-
trol. Optimized reverse transcription and PCR conditions
were as follows, TLR4 (48°C for 45 min followed by 95°C
for 2 min and 30 cycles at 95°C 30 sec, 56°C for 30 sec,
72°C for 60 sec), CD14, MD2 and MyD88 (48°C for 45
min followed by 95°C for 2 min and 28 cycles at 95°C 30
sec, 60°C 30 sec, 72°C for 1 min). For each experiment
RNA extracted from human monocyte U937 was used as
a positive control for TLR4, CD14, MD2 and MyD88. PCR
products were analyzed by electrophoresis on 2% agarose
gel. The gels were stained with CYBR safe DNA gel stain
(Molecular probe, Eugene, OR, USA) and visualized
under an ultraviolet transilluminator. The 100 bp DNA
size marker (Invitrogen, Carlsbad, CA, USA) was also run
to determine approximate size of the product.
Immunoblotting
Immunoblotting was performed as described previously
[7]. To differentiate monocyte to machrophages, U937
cells were treated with PMA for 24 hours, washed and
incubated for another 24 hours before treated with LPS asBMC Cancer 2006, 6:281 http://www.biomedcentral.com/1471-2407/6/281
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indicated below. NB-1 cells were directly seeded in 35 mm
culture dish, treated with LPS (100 ng/ml) for various
time. The cell lysates were extracted by lysis buffer con-
taining 0.5 M Tris-HCL, 4% SDS and 2 mercaptoethanol,
and boiled at 80°C for 5 min. The protein concentration
of each sample was determined by BCA protein assay rea-
gent (Pierce, Rockford, IL, USA). An equal amount of pro-
tein (40 μg) was analyzed by SDS-polyacrylamide gel
electrophoresis under reducing conditions and transferred
to a membrane filter. The membranes were treated with
an appropriately diluted antibody for overnight. The
immune complexes were detected with a 1:5000 dilution
of horseradish peroxidase-conjugated protein G for 1 h
and the bands were visualized with a chemiluminesent
reagent (Pierce, Rockford, IL). The chemiluminescence
was analyzed by a light capture system (AE6955, Atto
Corp., Tokyo, Japan) with CS grab, version 1.0. Densimet-
ric analysis of each band was analyzed with CS analyzer
software, version 1.0 (Atto Corp., Tokyo, Japan).
Luciferase reporter gene assay for NF-κB activation
The luciferase reporter gene assay was performed as
described previously [10]. Briefly, NB-1 cells (3 × 105/ml)
were plated in a 35 mm plastic dish. On the following day,
the cells were transfected with 0.5 mg/ml of pNF-κB-TA-
luc luciferase reporter gene (Invitrogen, Carlsbad, CA,
USA) and 0.05 mg of pRL-TK plasmid (Promega, Madi-
son, WI, USA) by lipofectamine 2000 transfection reagent
(Gibco-BRL). The transfected cells were incubated for 48
h, stimulated with LPS (100 ng/ml) and IL-1β (100 ng/
ml) for 6 h, lysed with a lysis reagent from Promega, and
the luciferase activity was determined by the dual luci-
ferase assay kit (Promega). To confirm the activation of
NF-κB, we used another plasmid pNiFty2-Luc from Invi-
vogen, San-Diego, CA, USA.
Statistical analysis
Statistical significance was determined by Student's t test.
Experimental result is expressed as the mean of triplicates
± SD in at least 3 independent experiments.
Results
NB-1 cells express TLR4
By using RT-PCR, we investigated whether human neu-
roblastoma cell line NB-1 expresses TLR4 or not. NB-1
cells were also treated with or without LPS (100 ng/ml)
for 4 hr. The expression of TLR4 was examined with RT-
PCR using extacted RNA. As shown in Fig. 1, NB-1 cells
definitely express TLR4 mRNA (Fig 1A, lane 2). LPS treat-
ment did not affect the expression of TLR4 (Fig 1A, Lane
3). To exclude the exceptional expression of TLR4 in NB-
1 cells, we examined TLR4 expression in another human
neuroblastoma cell line SK-N-SH. RT-PCR analysis dem-
onstrated that SK-N-SH cell line as well as NB-1 cell line
expressed TLR4 mRNA (Fig. 1B), suggesting that two neu-
roblastoma cell lines might commonly express TLR4.
Intracellular but not cell surface expression of TLR4 in NB-
1 cells
In mammalian cells, TLRs are expressed either on cell sur-
face or in the cytoplasm i.e golgi apparatus [11]. For exam-
ple, TLR1, TLR2 and TLR4 are located on cell surface and
are recruited to phagosomes after activation by their
respective ligands whereas TLR3, TLR7 and TLR9 which
recognize nucleic acid-like structures are located in subcel-
lular compartment [12-16]. First, we investigated the cell
surface expression of TLR4 on NB-1 cells with flow cyto-
metric analysis. NB-1 cells were stained with either PE-
conjugated anti-human TLR4 antibody or PE-conjugated
isotype matched IgG. Positively stained cells were not
Expression of TLR4 mRNA in NB-1 and SK-N-SH neuroblas- toma cells Figure 1
Expression of TLR4 mRNA in NB-1 and SK-N-SH neuroblas-
toma cells. A, NB-1 cells were incubated with LPS at 100 ng/
ml for 4 h. Untreated NB-1 (1), LPS-treated NB-1 cells (2) 
and untreated U937 cells (3) were analyzed by RT-PCR. B, 
SK-N-SH cells (l) and U937 cells (2) were analyzed by RT-
PCR. GAPDH mRNA was used as an equal loading control. 
Lane 4 and Lane 3 of each figure is used as a negative control 
respectively i.e RNA without reverse transcriptase enzyme 
(R.T). Data is the representative of at least three independ-
ent experiments.BMC Cancer 2006, 6:281 http://www.biomedcentral.com/1471-2407/6/281
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detected in NB-1 cells (Fig 2A), suggesting no cell surface
expression of TLR4. In addition, U937 cells as positive
control were strongly positive for TLR4. Second, we exam-
ined the intracellular expression of TLR4 using permeabi-
lized NB-1 cells because RT-PCR analysis demonstrated
the presence of TLR4 mRNA. The histogram of permeabi-
lized NB-1 cells stained by anti-TLR4 antibody shifted to
the right side (Fig. 2B), suggesting the intracellular locali-
zation of TLR4.
NB-1 cells express CD14, MD2 and MyD88 which 
participate in TLR4 signaling pathway
There are several key molecules leading to TLR4-depend-
ent cellular activation by LPS. Besides TLR4, a series of
molecules, such as CD14, MD2 and MyD88 are essential
for LPS response [17,18]. First, we studied the expression
of CD14, MD2 and MyD88 mRNA on NB-1 cells. RNA
was extracted from NB-1 cells treated with or without LPS
(100 ng/ml) for 4 hr and used to RT-PCR for CD14, MD2
and MyD88. RT-PCR analysis demonstrated that mRNAs
of the three molecules are expressed in NB-1 cells (Fig. 3).
In addition, LPS treatment did not alter their expression in
NB-1 cells. Human monocytic cell line U937 as a positive
control was also positive for CD14, MD2 and MyD88
mRNA. Laser flow cytometric analysis demonstrated cell
surface expression of CD14 in NB-1 cells (Data not
shown).
LPS partially degrades IκB-α
It has been well documented that NF-κB associated with
IκB resides in cytoplasm as an inactive form. On the proc-
ess of NF-κB activation, IκBα is rapidly phosphorylated
and degraded and then free NF-κB is translocated to
nucleus [19]. In order to investigate whether LPS is able to
activate NF-κB via intracellular TLR4, we examined degra-
dation of IκB-α in NB-1 cells treated with LPS (100 ng/ml)
for various time. As shown in Fig. 4, the expression of IκB-
α partially decreased up to 30 min after LPS treatment and
it returned to the original state 45 and 60 min after LPS
treatment. The possibility that a small amount of contam-
inants in the LPS preparation might induce the partial
activation still remained.
LPS does not activate NF-κB in NB-1 cells
Based on partial degradation of IκB-α upon LPS treat-
ment, we studied the activation of NF-κB by NF-κB-
dependent luciferase assay. NB-1 cells transfected with the
reporter gene were treated with LPS at various concentra-
tions for 6 h. Human IL-1β as a positive inducer [20] was
used at 100 ng/ml for 6 hr and the NF-κB activity was
determined with a relative luciferase activity. LPS at 5 μg/
ml failed to activate NF-κB activity in NB-1 cells whereas
IL-1β markedly enhanced it (Fig. 5). Further, we tried
another NF-κB-inducible reporter plasmid pNiFty2-Luc to
detect NF-κB activation. However, LPS failed to activate
NF-κB although IL-1β activated it significantly. Further,
treatment with LPS for 24 h did not induce NF-kB-
dependent TNF-α production in NB-1 cells (data not
shown).
NB-1 cells do not express IRF-3
Among all TLRs, only TLR3 and TLR4 can induce cellular
activation in both MyD88 dependent and independent
pathway [21]. In the MyD88-independent pathway, LPS
treatment leads to activation of transcription factor IRF-3,
followed by production of IFN-β. Subsequently, IFN-β
activates STAT1, leading to the induction of several IFN-
inducible genes [22-24]. We examined a possibility that
NB-1 cells might have a defect in MyD88-independent
pathway, especially IRF-3. Immunoblotting analysis dem-
onstrated that LPS induces phosphorylation of IRF-3 in
U937 but not in NB-1 cells. (Fig. 6A). Further, we exam-
ined the expression of IRF-3 in NB-1 cells and U937 cells.
Immunoblotting analysis demonstrated that NB-1 cells
did not express IRF-3 (Fig. 6B) although it was definitely
expressed in U937 cells.
LPS does not activate MAP kinases in NB-1 cells
LPS is known to activate JNK1/2 and p38 MAP kinases
through TAK1, a downstream molecule of TLR4-mediated
signaling pathway [25]. We examined the activation of
JNK1/2 and p38 MAP kinases in LPS-treated NB-1 cells.
LPS did not activate JNK1/2 and p38 MAP kinases in NB-
1 cells until 60 min (Fig. 7) whereas LPS activated them at
30 min in U937 cells. In addition, the treatment with LPS
for 2 h also failed to activate p38 and JNK1/2 in NB-1 cells
(data not shown).
Discussion
In the present study we have demonstrated that NB-1 and
SK-N-SH neuroblastoma cells express intracellular TLR-4.
On the other hand, SHSY-5Y neuroblastoma cells are
reported to express no TLR4 at mRNA level [2]. Therefore,
there seemed to be a difference in TLR4 expression among
various neuroblastoma cell lines. Although TLR4 is usu-
ally expressed on cell surface, there are a number of
reports on intracellular expression of TLR4 in various cell
types and cell lines, such as human placenta, coronary
artery endothelial cells, dendritic cells, pulmonary epithe-
lial cells, and intestinal epithelial cells m-ICc12 [11,26-
29]. Further, intracellular TLR4 is reported to responds to
LPS [11,26-29]. However, NB-1 cells expressing intracellu-
lar TLR4 did not respond to LPS.
NB-1 neuroblastoma cells express TLR4, MD2, CD14 and
MyD88, which are required for LPS signaling. LPS slightly
degraded IκB-α but did not significantly lead to NF-κB
activation in NB-1 cells. On the other hand, NF-κB signal-
ing acts normally because IL-1β induced the activation of
NF-κB in those cells. Therefore, intracellular TLR4 expres-BMC Cancer 2006, 6:281 http://www.biomedcentral.com/1471-2407/6/281
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Expression of CD14, MD2 and MyD88 in NB-1 cells Figure 3
Expression of CD14, MD2 and MyD88 in NB-1 cells. NB-1 
cells were incubated with or without LPS at 100 ng/ml for 4 
h. RNA was extracted and used for RT-PCR. Lane 1, 
untreated NB-1 cells; lane 2, LPS-treated NB-1 cells; lane 3, 
untreated U937 cells. Lane 4 is used as a negative control i.e 
RNA without reverse transcriptase enzyme (R.T). Data is the 
representative of at least three independent experiments.
Intracellular localization of TLR4 in NB-1 cells Figure 2
Intracellular localization of TLR4 in NB-1 cells. A, NB-1 cells were stained with no antibody, PE-conjugated isotype match IgG 
or PE-conjugated anti-TLR4 antibody. B, Permeabilized NB-1 cells were stained with the same protocol. The fluorescent histo-
gram was analyzed by a laser flow cytometer. Data is the representative of at least three independent experiments.
Effect of LPS on IκB-α degradation in NB-1 cells Figure 4
Effect of LPS on IκB-α degradation in NB-1 cells. NB cells 
were cultured with LPS at 100 ng/ml for various time and cell 
extracts were analyzed with immunoblotting using anti-IκB-α 
antibody. Densitometric analysis of each IκB-α band was per-
formed by a CS analyzer (top). A typical experimental result of 
three independent experiments is shown.BMC Cancer 2006, 6:281 http://www.biomedcentral.com/1471-2407/6/281
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sion might be involved in the unresponsiveness of NB-1
cells to LPS. LPS may not be internalized in NB-1 cells.
Otherwise, internalized LPS may undergo deacylation by
lysomal enzymes and become inactive before reaching
Golgi apparatus where TLR4 reside. Further, we can not
exclude a possibility that the LPS unresponsiveness may
be due to deficiency of some molecule(s) required for LPS
signaling. Interestingly, we found no expression of IRF-3
in NB-1 cells. Kawai et al. reported that IRF-3 plays a cen-
tral role in MyD88-independent pathway [30]. Therefore,
the MyD88-independent pathway of LPS signaling may
not occur in NB-1 cells. The impairment of MyD88-inde-
pendent pathway with defected IFR-3 might be related to
the unresponsiveness of NB-1 cells to LPS.
Thieblemont et al. demonstrated that LPS is transported to
Golgi apparatus [31]. Further, Hornef et al. reported that
TLR4 resides in the Golgi apparatus and cellular traffick-
ing of LPS to Golgi apparatus is important for innate
immune response [11]. On the other hand, there are sev-
eral contradictory reports on it. Latz et al. reported that
LPS traffics to the Golgi apparatus with TLR4-CD14-MD2
complex but does not initiate the signal transduction
pathway and that TLR4 must reside on cell surface to trig-
ger the signaling pathway, [32]. Even when LPS was artifi-
cially introduced into the cytoplasm, human coronary
epithelial cells were failed to activate due to its intracellu-
lar localization of TLR4 [33]. Our present study supports
a possibility that LPS might fail in triggering NF-κB activa-
Effect of LPS on IRF-3 activation in NB-1 cells Figure 6
Effect of LPS on IRF-3 activation in NB-1 cells. NB-1 cells 
were cultured with LPS at 100 ng/ml for various time as indi-
cated. Cell extracts were analyzed with immunoblotting 
using an antibody to phosphorylated form of IRF-3 (pIRF-3) 
(A) or total IRF-3 (B). U937 cells were used as a positive 
control. Equal loading is shown using anti-actin antibody. A 
typical experimental result of three independent experiments 
is shown.
Effect of LPS on NF-κB activation in NB-1 cells Figure 5
Effect of LPS on NF-κB activation in NB-1 cells. Transfected 
NB-1 cells were treated with LPS at various concentrations 
for 6 h. The NF-κB activity was expressed as relative luci-
ferase activity by fold increase. IL-1β (0.1 μg/ml) was used as 
a positive inducer of NF-κB. A typical experimental result of 
three independent experiments is shown.BMC Cancer 2006, 6:281 http://www.biomedcentral.com/1471-2407/6/281
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tion in NB-1 cells through intracellular TLR4 expression or
impaired MyD88-independent signaling.
Conclusion
In this report we for the first time demonstrate that neu-
roblastoma cells express TLR4 at the cytoplasm but not at
the cell surface. We further showed that, neuroblastoma
cell line NB-1 does not respond to LPS. We conclude that
unresponsiveness to LPS might be due to intracellular
localization of TLR4 or lack of IRF-3 expression. Further
studies must be necessary to confirm the expression and
role of TLR4 in neuroblastoma cells and neuroblasts.
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